Study of a new treatment for Crohn's disease
Part of Digestive system clinical trials.
This trial tests an experimental drug for people with moderate to severe Crohn's disease who haven't responded well to other treatments. The drug aims to reduce inflammation and may help improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have had Crohn's disease for at least 3 months, confirmed by a scope test and biopsy.
- Your Crohn's must be moderate to severe, based on a specific score and a special endoscopy.
- You must have tried at least one Crohn's treatment (like steroids, immune-suppressing drugs, or biologics) and it didn't work well or you couldn't tolerate it.
- Your Crohn's must not be limited to the stomach, upper small intestine, or only the anal area.
- You cannot have certain complications like abscesses, strictures that block the bowel, or short bowel syndrome.
- You cannot have had more than 2 bowel surgeries or have a stoma (bag).
- You must not have active tuberculosis or untreated latent tuberculosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called SAR442970 for people with moderate to severe Crohn's disease who haven't had success with standard treatments or biologics. The goal is to see if it can reduce inflammation and improve symptoms.
This study tests an experimental oral pill (SAR441566) for people with moderate to severe Crohn's disease. It aims to see if the drug can reduce inflammation and improve symptoms, especially for those who have not had success with other treatments.
This trial tests new therapies for people with moderate to severe Crohn's disease or ulcerative colitis. It may help if your standard treatments aren't working well enough.
This study tests an oral medication called TAK-279 to see if it can safely reduce inflammation in the bowel for people with moderate to severe Crohn's disease who haven't had success with other treatments.
This trial is testing a new investigational treatment called TRX103 for adults with moderate to severe Crohn's disease that has not responded to at least two other advanced therapies. The study aims to see if this treatment can reduce inflammation and improve symptoms.
This study tests an oral medicine called MORF-057 for people with moderate to severe Crohn's disease. It aims to see if the drug can reduce inflammation and improve symptoms for those who haven't had success with other treatments.
Hear when a new Crohn’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.